Cavalry develops programmable growth factors designed to address unmet medical needs in orphan diseases. Their platform focuses on engineering novel therapeutic proteins with precise biological activity. This approach aims to create targeted treatments for rare conditions where current options are limited.
Funding
$29.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many growth factors and cytokines lack tissue specificity, leading to off-target effects and reduced therapeutic efficacy, especially in the treatment of rare and chronic diseases. Systemic administration can result in widespread activation of cellular pathways, causing adverse side effects and limiting the achievable therapeutic dose.
Solution
CAVALRY Biosciences engineers tissue-selective growth factors and cytokines to enhance their therapeutic efficacy and safety profiles. The company reprograms the tropism of existing proteins, directing their activity to specific tissues or cell types while minimizing off-target interactions. This targeted approach aims to improve treatment precision, reduce systemic toxicity, and ultimately improve patient outcomes in rare and chronic diseases. By creating programmable growth factors, CAVALRY Biosciences seeks to unlock new therapeutic possibilities with enhanced control and selectivity.
Target Audience
The primary target audience includes patients with rare and chronic diseases, as well as pharmaceutical companies seeking to develop more effective and targeted therapies.
Features
- Tissue-selective growth factors engineered for targeted delivery
- Reprogrammed protein tropism to minimize off-target effects
- Enhanced therapeutic efficacy through increased precision